🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

953 results for “injection” Clear

  1. Entyvio 108 mg solution for injection in pre-filled syringe, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis or Crohn’s Disease

    phase 3 small molecule active

    1 trial

  2. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  3. Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use

    Ipsen

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  4. Eylea 40 mg/mL solution for injection in a vial

    Lacuna Pharma Pty Ltd

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  5. FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA

    Fondazione Telethon ETS

    Higher-risk-myelodysplastic syndromes

    phase 3 small molecule active

    1 trial

  6. Fazirsiran Injection

    Takeda

    Alpha1-Antitrypsin Deficiency

    phase 3 small molecule active

    3 trials

  7. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  8. Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion

    AXIM BIOTECHNOLOGIES, INC.

    B-cell Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  9. Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  10. Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen

    Lacuna Pharma Pty Ltd

    Episodic and Chronic Migraine

    phase 3 small molecule active

    1 trial

  12. G-Pen (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 3 small molecule completed

    1 trial

  13. GS1191-0445 injection

    Gritgen Therapeutics Co.,

    Hemophilia A

    phase 3 small molecule active

    1 trial

  14. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  15. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

  16. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    The George Institute

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    phase 3 small molecule active

    1 trial

  17. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed), SODIUM CHLORIDE

    Pari Pharma GmbH

    External Genital Warts (EGW)

    phase 3 small molecule active

    1 trial

  18. Ginkgo Diterpene Lactone Meglumine Injection

    Universal Integrated

    Ischemic Stroke

    phase 3 small molecule active

    1 trial

  19. Ginkgo diterpene lactone meglumine injection

    Universal Integrated

    Ischemic Stroke, Acute

    phase 3 small molecule active

    1 trial

  20. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  21. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  22. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  23. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  24. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources